A pilot study of Growth Hormone in children with Phelan-McDermid syndrome
Results from a study testing the safety and feasibility of using growth hormone (GH) as a treatment in children with Phelan-McDermid syndrome has just been published.
PMSF Scientific Advisory Committee Revisits Definition of Phelan-McDermid Syndrome
The Phelan-McDermid Syndrome Foundation Scientific Advisory Committee has proposed a new classification system for Phelan-McDermid syndrome in an important new publication.
Phelan Lucky 2022 Is Here!
Phelan Lucky 2022 is an online campaign that takes place for a strict 22-day period—from Jan. 2, 2022, through Jan. 24, 2022! It’s also the only time of year to get your hands on the coveted “Phelan Lucky” T-shirt.
Jaguar Gene Therapy Will Target SHANK3 for Gene Therapy
JAG201 is designed to address mutation or deletion of the SHANK3 gene, a leading autism candidate gene, by delivering SHANK3 gene replacement therapy.
Phelan-Lucky 2021
This year was the largest and most successful campaign that we have had to date.As February draws to a close, the…
PMSF Announces Changes to Leadership
Effective February, 2021, Joe Sammartino has resigned from the board after four years of dedicated service. Joe is focusing on and enjoying time…